COMPANY PROFILE

hC Bioscience

Explore full profile

An innovator and pioneer of protein editing using context agnostic engineered tRNA

Cambridge, United StatesFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2021
Headquarters: Cambridge, United States
Employees: 3
Open positions: None listed
Dealroom signal: 61.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Technology: Virtual Reality
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Feb 2023	$0	—	CureDuchenne Ventures	↗
SERIES A✓Equity / VC	Nov 2022	$16M	$120M	ARCH Venture Partners · 8VC · Taiho Ventures · Takeda Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

hC Bioscience website traffic

Latest recorded traffic for hC Bioscience is 750 monthly website visits, down 46.4% over the last three months. hC Bioscience's team declined 50% over the past year.

Latest monthly visits750 3-month web change-46.4% 1-year team growth-50%

Monthly website visitsNov 2022–Aug 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
CTCyclone TherapeuticsA preclinical-stage drug discovery company that focuses on improving protein quality control by modulating translation	San Diego, United States	Operational	1	$800K	$3.2M
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational
MOMoleculeMindA leading AI protein design platform company	Haidian, China	Operational
ELEarendil LabsAI Solutions to Protein-based Therapeutics	China	Operational
ATApertura Gene TherapyLeverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies	New York City, United States	Operational
CECellshootSearching for drug discovery target molecules and create groundbreaking new drug candidates	Tokyo, Japan	Operational
MTMatwings TechnologyLeveraging its independently developed general AI for protein design, AccelProtein	Minhang District, China	Operational
ETEngimmune TherapeuticsPlatform and product development company engineering next-generation T cell receptor therapies	Allschwil, Switzerland	Operational